Onkure Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Onkure Therapeutics Inc 's ROA in the second quarter of 2026?
Onkure Therapeutics Inc recorded a cumulative net loss of $-59 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -44.84%.

However, within the Healthcare sector 534 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3990, from total ROA ranking in the first quarter of 2026 at 4834.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	120.82 %	98.93 %	-45.94 %	-6.19 %	9.34 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-59	-59	-60	-63	-60
Return On Assets (TTM)	-44.84 %	-55.99 %	-74.19 %	-67.92 %	-63.74 %
OKUR's Total Ranking	# 3990	# 4834	# 4194	# 4226	# 4304
Total Assets (TTM) in million	190	199	62	73	86
Seq. Total Assets Change	-4.35 %	219.87 %	-14.72 %	-15.38 %	-13.83 %
Seq. Net Income Change	-	-	-	-	-

OKUR's 5 Years Annual ROA >> Back to OKUR Management Effectiveness >> Compare OKUR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 225
Sector	# 535
Overall	# 3841

Return On Assets Statistics
High	Average	Low
-27.26 %	-55.87 %	-84.97 %
(Dec 31 2021)		(Sep 30 2024)

Financial Statements
Onkure Therapeutics Inc 's Assets	$ 190 million	OKUR's Balance sheet
Onkure Therapeutics Inc 's Income	$ -15 million	Quarterly OKUR's Income Statement
OKUR's Income by Division		See OKUR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-45.94 %	6.95 %	-0.34 %	-30.01 %	-
Total Assets in million	62	115	107	108	154
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-60	-53	-77	-52	-40
Annual Return On Assets	-95.81 %	-45.84 %	-72.03 %	-48.19 %	-25.82 %

OKUR's 5 Years Annual ROA >> Back to OKUR Management Effectiveness >> Compare OKUR ROA to its Competitors

More Return On Assets Ratios
OKUR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OKUR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OKUR's Competitors
Subscribers only: Roa for Onkure Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for OKUR's Customers

You may also want to know
OKUR's Roi	OKUR's Inventory Turnover Ratio	OKUR's Growth Rates	OKUR's Dividend Comparisons
	OKUR's Profitability Ratios	OKUR's Asset Turnover Ratio	OKUR's Dividend Growth
OKUR's Roe	OKUR's Valuation Ratios	OKUR's Financial Strength Ratios	OKUR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T21:24:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.